CRSP — CRISPR Therapeutics AG

—
Nasdaq · Health Care · Biotechnology · CIK 1674416 · Switzerland
Last close
$40.15
Market Cap
$3.89B
52W High
$63.45
52W Low
$39.79
ADV30
1,729,341
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 12,323,000 -28,961,000 -118,370,000 -111,437,000 2,556,412,000 192,027,000 908,344,000
Jun 2026 10,000,000 -30,272,000 -117,269,000 -91,154,000 2,650,770,000 291,337,000 904,219,000
Mar 2026 1,000,000 -44,949,000 -130,248,000 -122,931,000 2,725,820,000 423,308,000 911,264,000
Dec 2025 0 -53,703,000 -154,764,000 -130,613,000 2,265,243,000 347,559,000 343,430,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-374,632,000
Investing CF
$-443,289,000
Financing CF
$719,956,000
CapEx
$-4,216,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-4.74
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,273,073,000
Inventory
—
Receivables
$0
ST Investments
$2,080,521,000
EBIT TTM
$-518,178,000
Pretax Income TTM
$-453,648,000
Interest Exp TTM
—
Analysts
19

Yahoo Snapshot (yfinance, live)

Total Revenue
$25,172,000
EBITDA
$-499,680,000
Free Cash Flow
$-215,401,248
Enterprise Value
$3,364,109,824
Total Cash
$2,272,548,096
Total Debt
$779,827,008
Shares Out
97,000,813
Trailing EPS
$-4.73
Book Value
$17.02
ROE
-25.6%
ROA
-13.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -664,571,000 -581,599,000 2,265,243,000 343,430,000 1,921,813,000 -345,014,000
Dec 2024 35,000,000 -466,566,000 -366,252,000 2,242,034,000 309,954,000 1,932,080,000 -142,774,000
Dec 2023 370,000,000 -222,538,000 -153,610,000 2,229,571,000 346,768,000 1,882,803,000 -260,375,000
Dec 2022 436,000 -673,161,000 -650,175,000 2,243,057,000 367,578,000 1,875,479,000 -495,741,000

TTM Snapshot

Revenues TTM
$13,392,000
NetIncome TTM
$-451,139,000
OpCashFlow TTM
—
Assets (Latest)
$2,650,770,000
Forward EPS
$-3.69

Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $42.50 · spot: $40.19 · call volume: 791 · put volume: 104
Expected Move to 2027-04-16: ±$11.82 (29.41%) — implied range $28.37 – $52.01 · ATM straddle on $40.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TARS Tarsus Pharmaceuticals, Inc. $3.86B $78.20 —
RLAY Relay Therapeutics, Inc. $3.64B $16.47 —
IOVA IOVANCE BIOTHERAPEUTICS, INC. $3.48B $7.53 —
ADPT Adaptive Biotechnologies Corp $4.61B $28.49 —
ADMA ADMA BIOLOGICS, INC. $3.02B $13.63 —

News headlines (Yahoo Finance, 1h cache)

Is CRISPR Therapeutics (CRSP) Undervalued As CTX310 Data Meets a Share Price Slide?
2026-11-18 11:09 · Yahoo
CRISPR Therapeutics (CRSP) Stock Could Be Above Fair Value On Its 50% Five Year Fall
2026-11-18 10:13 · Yahoo
CRISPR Therapeutics (CRSP) Flags Early CTX310 And Zugo Cel Wins In Two Big Markets
2026-11-18 09:10 · Yahoo
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
2026-11-17 13:00 · Yahoo
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
2026-11-17 12:13 · Yahoo
Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
2026-11-16 10:00 · Yahoo
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-11-10 13:30 · Yahoo
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scient
2026-11-09 14:16 · Yahoo
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
2026-11-08 15:30 · Yahoo
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
2026-11-06 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.